The Effect of Topical 0.05% Cyclosporine on Recurrence Following Pterygium Surgery

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2011 Jul 16

PMID 21760716

Citations 12

Authors

Ece Turan-Vural

Banu Torun-Acar

S Argun Kivanc

Suphi Acar

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis(®), Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique.

Methods: In this prospective randomized controlled study, 36 eyes (34 patients) with primary pterygium were randomized into two groups: Group I comprised 18 eyes (18 patients), and Group II comprised 18 eyes (16 patients). Bare sclera technique was performed in both groups. In Group I, 0.05% CsA was administered postoperatively at 6-hour intervals for 6 months, and Group II did not receive any cyclosporine treatment. The patients were assessed for recurrence, side effects, and complications at postoperative 1 and 7 days as well as each month during the following year. Conjunctival advances which showed a limbus higher than 1 mm were recognized as recurrence.

Results: Recurrence occurred in four patients (22.2%) in Group I and in eight (44.4%) patients in Group II.

Conclusion: Postoperative application of low-dose CsA can be effective for preventing recurrences after primary pterygium surgery.

Citing Articles

Application of topical 2% cyclosporine A in inflammatory ocular surface diseases.

Asena L, Altinors D Int Ophthalmol. 2023; 43(11):3943-3952.

PMID: 37420126 DOI: 10.1007/s10792-023-02796-x.

Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence.

Raina U, Pavitra B, Bhattacharya S, Ravinesh K, Goel R Oman J Ophthalmol. 2023; 16(1):30-34.

PMID: 37007236 PMC: 10062085. DOI: 10.4103/ojo.ojo_56_22.

Clinical Results of the Use of Amniotic Membrane Transplantation Alone or in Combination with Adjuvant Therapies in Conjunctival Fornix Reconstruction.

Aslan Katircioglu Y, Kaderli A, Ozdemir E, Ornek F Turk J Ophthalmol. 2022; 52(4):237-245.

PMID: 36016847 PMC: 9421934. DOI: 10.4274/tjo.galenos.2021.77019.

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery.

Karadag A, Guler E Beyoglu Eye J. 2022; 6(3):185-190.

PMID: 35005514 PMC: 8697054. DOI: 10.14744/bej.2021.68442.

Pterygium: an update on pathophysiology, clinical features, and management.

Shahraki T, Arabi A, Feizi S Ther Adv Ophthalmol. 2021; 13:25158414211020152.

PMID: 34104871 PMC: 8170279. DOI: 10.1177/25158414211020152.

References

Di Girolamo N, Chui J, Coroneo M, Wakefield D . Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004; 23(2):195-228. DOI: 10.1016/j.preteyeres.2004.02.002. View

Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H . Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997; 17(7):4015-23. PMC: 232254. DOI: 10.1128/MCB.17.7.4015. View

Wang I, Lai W, Liou S, Chiu C, Hu F, Kao W . Impression cytology of pterygium. J Ocul Pharmacol Ther. 2001; 16(6):519-28. DOI: 10.1089/jop.2000.16.519. View

Lee D, Cho H, Kim J, Choi J, Joo C . Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001; 20(7):738-42. DOI: 10.1097/00003226-200110000-00013. View

Di Girolamo N, Kumar R, Coroneo M, Wakefield D . UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2002; 43(11):3430-7. View

Mutlu F, Sobaci G, Tatar T, Yildirim E . A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology. 1999; 106(4):817-21. DOI: 10.1016/S0161-6420(99)90172-0. View

Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R . Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002; 89(3):298-303. DOI: 10.1016/S1081-1206(10)61958-8. View

Weinstein O, Rosenthal G, Zirkin H, Monos T, Lifshitz T, Argov S . Overexpression of p53 tumor suppressor gene in pterygia. Eye (Lond). 2002; 16(5):619-21. DOI: 10.1038/sj.eye.6700150. View

Strong B, Farley W, Stern M, Pflugfelder S . Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2004; 24(1):80-5. DOI: 10.1097/01.ico.0000133994.22392.47. View

10.

Chan C, Liu Y, Tan D . Ocular surface changes in pterygium. Cornea. 2002; 21(1):38-42. DOI: 10.1097/00003226-200201000-00009. View

11.

Yalcin Tok O, Nurozler A, Ergun G, Akbas Kocaoglu F, Duman S . Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica. 2008; 222(6):391-6. DOI: 10.1159/000151740. View

12.

Hercules L, Viveiros M, Schellini S, Candeias J, Padovani C . [Exposure of Tenon's capsule fibroblasts of pterygium to cyclosporin 0.05%]. Arq Bras Oftalmol. 2007; 69(6):831-5. DOI: 10.1590/s0004-27492006000600010. View

13.

Marcovich A, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A . Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res. 2003; 25(1):17-22. DOI: 10.1076/ceyr.25.1.17.9959. View

14.

Nakamura M, Nishida T . Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells. Cornea. 1999; 18(4):452-8. DOI: 10.1097/00003226-199907000-00011. View

15.

Dushku N, Reid T . P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res. 1998; 16(12):1179-92. DOI: 10.1076/ceyr.16.12.1179.5036. View

16.

Okudaira H, Sakurai Y, Terada K, Terada E, Ogita T, Miyamoto T . Cyclosporin A-induced suppression of ongoing IgE antibody formation in the mouse. Int Arch Allergy Appl Immunol. 1986; 79(2):164-8. DOI: 10.1159/000233965. View

17.

Solomon A . Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1985; 99(2):216-7. DOI: 10.1016/0002-9394(85)90243-0. View

18.

Hill J, Maske R . Pathogenesis of pterygium. Eye (Lond). 1989; 3 ( Pt 2):218-26. DOI: 10.1038/eye.1989.31. View

19.

Tan D, Tang W, Liu Y, Goh H, Smith D . Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol. 2000; 84(2):212-6. PMC: 1723383. DOI: 10.1136/bjo.84.2.212. View

20.

van Setten G, Aspiotis M, Blalock T, Grotendorst G, Schultz G . Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor - possible contributing factor to conjunctival scarring. Graefes Arch Clin Exp Ophthalmol. 2003; 241(2):135-9. DOI: 10.1007/s00417-002-0589-1. View